SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors

• Published in: Molecular imaging and biology Vol. 17; no. 3; pp. 313 - 318
• Main Authors: Kratochwil, C., Stefanova, M., Mavriopoulou, E., Holland-Letz, T., Dimitrakopoulou-Strauss, A., Afshar-Oromieh, A., Mier, W., Haberkorn, U., Giesel, F. L.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.06.2015; Springer Nature B.V
• Subjects: Aged; Brief Article; Contrast Media; Female; Humans; Imaging; Liver Neoplasms - diagnostic imaging; Liver Neoplasms - pathology; Liver Neoplasms - secondary; Male; Medicine; Medicine & Public Health; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neuroendocrine Tumors - diagnostic imaging; Octreotide - analogs & derivatives; Octreotide - chemistry; Organometallic Compounds - chemistry; Peptides - chemistry; Positron-Emission Tomography; Probability; Radiology; Radiopharmaceuticals - chemistry; Receptors, Somatostatin - chemistry; Receptors, Somatostatin - metabolism; ROC Curve; Tomography, X-Ray Computed; Peptide-related radionuclide therapy; Ga]DOTATOC; Somatostatin receptor; [; SUV; Neuroendocrine tumors

Purpose The goal of our study was to quantify the expression of the somatostatin receptors (SSTR2) using the maximum standardized uptake value (SUVmax) of [ 68 Ga]DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTATOC) positron emission tomography (PET)-computed tomography (CT) in liver metastases of patients wi...